portfolio and licensing

Biopharma mega mergers remain a force: Q1 analysis

During the first  quarter of 2019, Cortellis Deals Intelligence registered 124 new mergers and acquisitions (M&A), a 24% increase from 100, quarter on quarter vs. last year, as part of its ongoing coverage of M&A activity in the life sciences sector (see Figure 1). However, total disclosed deal value declined by 9% to $119.2 billion […]

Oncology, dermatology, hematology pace Q1 biopharma licensing

During the first quarter of 2019, Cortellis Deals Intelligence registered 1,023 new deals (excluding mergers & acquisitions) as part of its ongoing coverage of licensing activity in the life sciences sector, a minor decrease of 0.6% from 1,029 in Q1 a year ago. The total disclosed deal value rose to $44.9 billion, a 26.8% rise […]